Lithium is a monovalent alkali metal that has been used as a psychiatric medication since the 1940s and remains one of the most effective and extensively studied treatments for bipolar disorder, particularly for the prevention and treatment of manic episodes. What makes lithium unique among psychiatric medications is its extraordinary potency at low doses — therapeutic blood levels are maintained at 0.6-1.2 mmol/L, orders of magnitude lower than the doses used for other medical applications of lithium — and the breadth of its mechanisms of action, which span dozens of neurobiological pathways including neurotransmitter system regulation, neuroprotective signalling, inflammatory modulation, and cellular resilience. Lithium is also one of the few psychiatric medications with robust evidence for a disease-modifying effect: it appears to reduce the long-term progression of bipolar disorder, decrease suicide risk, and possibly slow cognitive decline in ageing brains.
Mechanisms of Action
Lithium produces its mood-stabilising effects through multiple intersecting mechanisms. At the neurotransmitter level, lithium reduces catecholamine neurotransmission (dopamine and noradrenaline) and enhances serotonergic neurotransmission — these opposing effects on different neurotransmitter systems help explain its unique ability to reduce both mania and depression without worsening either pole of the illness. Lithium also inhibits the inositol monophosphatase (IMPase) enzyme, which reduces the availability of phosphatidylinositol (PI) for second messenger signalling — this effect is more pronounced in the brains of bipolar patients, where the PI signalling system appears to be overactive. Lithium also activates the Wnt/beta-catenin pathway, which is a key neurodevelopmental and neuroprotective signalling cascade that promotes neuronal survival, synaptic plasticity, and the expression of brain-derived neurotrophic factor (BDNF).
At the cellular level, lithium enhances neuroplasticity and cellular resilience through its activation of the BDNF pathway and its promotion of mitochondrial biogenesis. Lithium also has anti-inflammatory effects — it reduces the production of pro-inflammatory cytokines (IL-6, TNF-alpha) by activated microglia, which may contribute to its therapeutic effects in a subset of bipolar patients where neuroinflammation is a contributing mechanism. The convergence of these multiple mechanisms on mood stabilisation and neuroprotection makes lithium one of the most pharmacologically sophisticated treatments in psychiatry — and one of the few that appears to address the underlying pathophysiology of bipolar disorder rather than simply suppressing its symptoms.
Clinical Evidence for Bipolar Disorder
Lithium is the gold standard treatment for bipolar disorder maintenance therapy. A meta-analysis of 39 RCTs in bipolar disorder found that lithium significantly reduced the risk of manic and depressive episode recurrence compared to placebo, with an effect size that is larger than any other mood stabiliser or antipsychotic medication used in bipolar disorder. Lithium also significantly reduces the risk of suicide — a meta-analysis of 38 studies found that lithium treatment was associated with approximately 80% lower suicide risk compared to placebo, independent of its effects on mood episode recurrence. This anti-suicidal effect is one of the most robust findings in psychiatry and is unique to lithium among mood stabilisers — valproate, carbamazepine, and lamotrigine do not show the same consistent anti-suicidal effect. Lithium also has evidence for reducing aggression and impulsivity in prisoners and in patients with personality disorders, though these uses are less well-studied.
Neuroprotective Effects and Cognitive Ageing
Beyond its effects on mood stabilisation, lithium has consistently demonstrated neuroprotective effects in both animal and human studies. Lithium activates the glycogen synthase kinase 3 beta (GSK-3beta) pathway in a way that promotes neuronal survival and inhibits the tau protein phosphorylation that is characteristic of Alzheimer disease neuropathology. Studies in patients with bipolar disorder show that long-term lithium treatment is associated with increased grey matter volume in the prefrontal cortex and hippocampus (regions critical for memory and emotional regulation), increased BDNF levels in serum, and improved performance on cognitive tests of verbal memory and executive function. These findings suggest that lithium may have disease-modifying effects that extend beyond symptom suppression — possibly protecting against the neurodegenerative processes that contribute to cognitive decline in bipolar disorder and in normal ageing.
Practical Application and Safety
For bipolar maintenance, therapeutic blood levels of 0.6-1.2 mmol/L are targeted, which typically requires doses of 600-1,200mg of lithium carbonate daily. Lithium has a narrow therapeutic index — the difference between therapeutic and toxic blood levels is small — so blood level monitoring is essential. Side effects at therapeutic levels include polyuria and polydipsia (due to lithium interference with the kidney concentrating mechanism, producing nephrogenic diabetes insipidus), weight gain, hypothyroidism (due to lithium interference with thyroid hormone synthesis), and tremor. The kidney effects of lithium are the primary concern with long-term use: chronic lithium nephropathy (a decrease in kidney function developing over years of use) is a recognised complication that requires monitoring of renal function every 6-12 months. Adequate hydration is essential for anyone using lithium to prevent lithium accumulation and toxicity. Lithium is contraindicated in pregnancy (associated with Ebstein anomaly, a cardiac malformation) and should be used with caution in people with kidney disease or heart failure.
Leave a Reply